Why the study?
Does dabigatran or rivaroxaban improve efficacy and safety compared to enoxaparin for thromboprophylaxis in patients undergoing hip or knee arthroplasty?
Does dabigatran or rivaroxaban improve efficacy and safety compared to enoxaparin for thromboprophylaxis in patients undergoing hip or knee arthroplasty?
In patients undergoing major joint arthroplasty, rivaroxaban is more effective than enoxaparin but carries a higher bleeding risk, whereas dabigatran and enoxaparin have similar efficacy and safety profiles.
Answers are grounded in this paper and cite their sources.
Rivaroxaban improves VTE prevention over enoxaparin at higher bleeding cost while dabigatran matches enoxaparin; confirms NOAC-specific trade-offs for arthroplasty thromboprophylaxis.
BACKGROUND: Dabigatran and rivaroxaban are novel oral anticoagulants approved for prevention of venous thromboembolism after hip or knee arthroplasty. However, information assessing clinically important efficacy and bleeding outcomes of these 2 new agents versus low-molecular-weight heparin (enoxaparin) is lacking. METHODS AND RESULTS: We separately pooled efficacy and safety data from 6 phase III randomized trials (18 405 participants) comparing equivalent durations of treatment with enoxaparin (40 mg once daily [od] or 30 mg twice daily) versus dabigatran (220 mg od) or versus rivaroxaban (10 mg od) after hip or knee arthroplasty. Odds ratios (OR) for individual outcomes were calculated for each trial and were pooled using the Mantel-Haenszel method. Compared with dabigatran, enoxaparin had a similar risk of symptomatic venous thromboembolism plus all-cause mortality (0.9% versus 1.1%; OR, 0.76; 95% confidence interval [CI], 0.44 to 1.31; I²=76%) and bleeding (5.0% versus 5.6%; OR, 0.90; 95% CI, 0.71 to 1.15; I²=0%). Compared with rivaroxaban, enoxaparin had a 2-fold higher risk of symptomatic venous thromboembolism plus all-cause mortality (1.2% versus 0.6%; OR, 2.04; 95% CI, 1.32 to 3.17; P<0.001; number needed to treat, 167; I²=0%) but demonstrated a significant lower risk of bleeding (2.5% versus 3.1%; OR, 0.79; 95% CI, 0.62 to 0.99; P=0.049; number needed to harm, 167; I²=0%). CONCLUSIONS: In patients undergoing hip or knee arthroplasty, enoxaparin and dabigatran showed similar rates of efficacy and bleeding. Enoxaparin was less effective than rivaroxaban but had a lower risk of bleeding. These results may have important implications for the choice of prophylactic agent in major joint arthroplasty.
No takes yet. Share an insight, caveat, or question.
Huisman et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: